Search Results 1551-1560 of 21919 for Inhibition

1. Heart Failure Clinical Trials - Mayo Clinic Research

   The purpose of this study is to determine the effect of a single dose of an oral acute MPO inhibitor ... Circulating NEP and NEP Inhibition Study in Heart Failure ...

2. A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets - Mayo Clinic

   therapy, including a proteasome inhibitors (PI), an ... - Permitted to be venetoclax or BCL-2 inhibitor exposed in previous lines of therapy.

3. A Study of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant - Mayo Clinic

   Previous allergic reactions to Janus kinase (JAK) inhibitors or excipients. ... Concomitant use of any JAK inhibitor. Initiating therapy with any ...

4. Cellular Responses to DNA Damage Induced by Topoisomerase Poisons - Anticancer Drug Action Laboratory - Mayo Clinic Research

   Building on these results, we're now investigating the possible beneficial effects of combining ATR inhibitors with topoisomerase I poisons in preclinical ...

5. Medtronic study with Personalized Closed Loop - Mayo Clinic

   Subject is using pramlintide (Symlin), DPP-4 inhibitor, liraglutide ... inhibitors) at time of Visit 1. Subject has a history of visual impairment ...

6. Lisocabtagene maraleucel (intravenous route) - Side effects & uses - Mayo Clinic

   ... inhibitor, BCL-2 inhibitor) that did not work well. Lisocabtagene maraleucel injection is also used to treat follicular lymphoma (FL) that has come back ...

7. Publications - Nadine H. Abdallah, M.D. - Mayo Clinic

   ... inhibitors. Lung Cancer (Auckl). 2019; 10:95-105 Epub 2019 Sept 12. View PubMed; Kanj A, Abdallah N, Soubani AO. The spectrum of pulmonary aspergillosis ...

8. A Study Comparing X-396 (Ensartinib) to Crizotinib in Patients with ALK Positive Non-Small Cell Lung Cancer - Mayo Clinic

   ... inhibitor. Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns ...

9. Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia - Mayo Clinic

   ... inhibitor 2A [CDKN2A]/Cen9), and t(14;var) (immunoglobulin heavy chain [IGH] ... Patient must not be receiving protease inhibitors or once daily ...

10. Evaluation of the Zone-MPC Control Algorithm Integrated into the iAPS in Pregnant Patients with Type 1 Diabetes - Mayo Clinic

    ... inhibitors, SGLT-2 inhibitors, sulfonylureas). Hemophilia or any other bleeding disorder. Prior history of Preterm Premature Rupture of Membranes (PPROM) ...